Liquidia Co. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 1,649 shares of the business's stock in a transaction on Friday, April 19th. The stock was sold at an average price of $13.68, for a total transaction of $22,558.32. Following the completion of the transaction, the insider now directly owns 211,672 shares in the company, valued at approximately $2,895,672.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Liquidia Stock Down 1.7 %
Liquidia stock opened at $12.95 on Wednesday. The company has a market cap of $984.59 million, a price-to-earnings ratio of -10.79 and a beta of 0.16. The firm's fifty day moving average is $14.64 and its 200 day moving average is $11.17. Liquidia Co. has a 52-week low of $5.71 and a 52-week high of $16.99.
Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.19). The business had revenue of $4.53 million for the quarter, compared to analysts' expectations of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, equities research analysts anticipate that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.
Analysts Set New Price Targets
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Several equities analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Liquidia from $16.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, March 14th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, Liquidia currently has an average rating of "Moderate Buy" and an average price target of $21.00.
View Our Latest Stock Analysis on Liquidia
Institutional Investors Weigh In On Liquidia
Hedge funds have recently bought and sold shares of the business. Bluefin Capital Management LLC bought a new stake in shares of Liquidia in the 4th quarter worth about $302,000. Birchview Capital LP bought a new stake in shares of Liquidia in the 4th quarter worth about $241,000. Kynam Capital Management LP lifted its holdings in shares of Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company's stock worth $32,461,000 after acquiring an additional 698,324 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Liquidia in the 4th quarter worth about $12,331,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company's stock worth $108,000 after acquiring an additional 7,731 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
